Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Severe, Recalcitrant Nodular Acne, Severe nodular acne unresponsive to conventional therapy, including systemic antibiotics Age: Adult |
Dose: Oral – 0.5-1 mg/kg/day Frequency: divided twice daily Duration: 15-20 weeks Note: Hepatic impairment: Contraindicated. |
|
Indication: Severe nodular acne with scarring or primarily manifested on the trunk Age: Adult Condition: very severe |
Dose: Oral – up to 2 mg/kg/day Note: As tolerated. Hepatic impairment: Contraindicated. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Severe, Recalcitrant Nodular Acne Age: less than 12 years |
Dose: PO – Safety and efficacy not established Note: Severe nodular acne unresponsive to conventional therapy, including systemic antibiotics |
|
Indication: Severe, Recalcitrant Nodular Acne Age: greater than 12 years |
Dose: PO – 0.5-1 mg/kg/day Frequency: twice daily Duration: 15-20 weeks Note: Severe nodular acne unresponsive to conventional therapy, including systemic antibiotics |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Severe renal impairment |
Dose: Reduce initial dose – 10 mg Frequency: once daily Note: Gradually increase to 1 mg/kg as necessary |
Administration
- Take with food
- Take twice daily
Side Effect
- Cheilitis (90%)
- Xerosis
- Xerostomia
- Dry nose
- Epistaxis
- Pruritus
- Conjunctivitis (including blepharoconjunctivitis) (40%)
- Irritation (40%)
- Increased erythrocyte sedimentation rates (40%)
- Thinning of hair (which has persisted in rare instances)
- Palmoplantar desquamation
- Skin fragility
- Skin infections (eg paronychial infections)
- Rash (including erythema
- seborrhea
- eczema)
- photosensitivity
- Hypertriglyceridemia (25%)
- Bone or joint pain
- Generalized muscle aches
- Arthralgia
- Decreased HDLs (15%)
- Increased LFTs (15%)
- Increased CPK (12-24%)
- Decreased hemoglobin concentration and hematocrit
- Decreased erythrocyte and leukocyte counts
- Increased platelet count
- Decreased bone mineral density (8.8%)
- Premature epiphyseal closure (3%)
- Lethargy
- Fatigue
- Headache
- Anorexia
- Nausea
- Vomiting
- Increased appetite
- Thirst
- Anaphylaxis
- Haemorrhagic pancreatitis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Vitamin A or its derivatives
|
Additive toxicity
|
|
Microdosed progesterone
|
Decreased efficacy (use 2 forms of contraception)
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Data not available
|
Data not available
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.